Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes

doi:10.4239/wjd.v16.i2.99928

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (171)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

125

Sum=134

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=22

Feb 15, 2025 (publication date) through Jan 9, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Diabetes. Feb 15, 2025; 16(2): 99928
Published online Feb 15, 2025. doi: 10.4239/wjd.v16.i2.99928

Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes

Gabriel Reis Rocha, Fabrício Freire de Melo

Gabriel Reis Rocha, Fabrício Freire de Melo, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45065-430, Bahia, Brazil

Author contributions: Rocha GR and de Melo FF contributed to review of the literature, and writing and editing of the manuscript; Rocha GR designed the overall concept and outline of the manuscript; de Melo FF contributed discussions for important intellectual concepts and design of the manuscript.

Supported by the Industrial Technological Initiation Scholarship of National Council for Scientific and Technological Development, CNPq, No. 0932204294929829; and the CNPq Research Productivity Fellow, No. 4357511882624145.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Fabrício Freire de Melo, PhD, Adjunct Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58, Vitória da Conquista 45065-430, Bahia, Brazil. freiremeloufba@gmail.com

Received: August 4, 2024
Revised: October 25, 2024
Accepted: November 4, 2024
Published online: February 15, 2025
Processing time: 149 Days and 5.7 Hours

Core Tip

Core Tip: Hypoglycemia is a common and significant phenomenon in type 1 diabetes, with recurrent episodes causing progressive dysfunction in glycemic counterregulation and reduced hypoglycemia awareness. The involvement of glucagon-like peptide 1 in this impairment is under investigation, but the pathophysiology is complex and multifactorial, involving various hormones and central receptors. Notwithstanding, studies on glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus have shown promising benefits and a favorable safety profile.